Sobi Maintains Grip On RSV Market – For Now
Though Competition Is Coming
Executive Summary
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
You may also be interested in...
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
Sobi To Start Selling Zynlonta After Sealing EU Approval
Five months after paying $55m upfront to Switzerland's ADC Therapeutics, Sobi has been granted conditional marketing authorization for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.